Dual targeting of PI3Kδ and PPARα enhances antitumor activity via FoxO1 activation in follicular lymphoma

Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆. Ann Oncol. 2021;32:298–308.

Google Scholar 

Dada R. Diagnosis and management of follicular lymphoma: a comprehensive review. Eur J Haematol. 2019;103:152–63.

Google Scholar 

Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10:74.

Google Scholar 

Ghione P, Palomba ML, Ghesquieres H, Bobillo S, Patel AR, Nahas M, et al. Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study. Haematologica. 2023;108:822–32.

Google Scholar 

Paik J-H, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007;128:309–23.

Google Scholar 

Dengler HS, Baracho GV, Omori SA, Bruckner S, Arden KC, Castrillon DH, et al. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol. 2008;9:1388–98.

Google Scholar 

Xing Y, Li A, Yang Y, Li X, Zhang L, Guo H. The regulation of FOXO1 and its role in disease progression. Life Sci. 2018;193:124–31.

Google Scholar 

Fu Z, Tindall DJ. FOXOs, cancer and regulation of apoptosis. Oncogene. 2008;27:2312–19.

Google Scholar 

Hlavac K, Pavelkova P, Ondrisova L, Mraz M. FoxO1 signaling in B cell malignancies and its therapeutic targeting. FEBS Lett. n/a. https://doi.org/10.1002/1873-3468.15057.

Xie L, Ushmorov A, Leithäuser F, Guan H, Steidl C, Färbinger J, et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood. 2012;119:3503–11.

Google Scholar 

Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov. 2021;20:741–69.

Google Scholar 

Su H, Wang T, Sun X, Qiu L, Cao J, Li Z, et al. PI3Kδ inhibitor linperlisib As a ≥ 3-line treatment for relapsed or refractory follicular lymphoma: a subgroup analysis of a phase II, single-arm, open-label trial. Blood. 2023;142:1677.

Google Scholar 

Fruman DA, Rommel C. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov. 2011;1:562–72.

Google Scholar 

Wang T, Sun X, Qiu L, Su H, Cao J, Li Z, et al. The oral PI3Kδ inhibitor linperlisib for the treatment of relapsed and/or refractory follicular lymphoma: a phase II, single-arm, open-label clinical trial. Clin Cancer Res. 2023;29:1440–49.

Google Scholar 

Pang Z, Wang Y, Liu Z, Zhang S, Wei C, Xu Z, et al. Linperlisib plus chidamide in relapsed or refractory cutaneous T-cell lymphoma: a nonrandomized clinical trial. JAMA Dermatol. 2025. https://doi.org/10.1001/jamadermatol.2025.1926.

Jin J, Cen H, Zhou K, Xu X, Li F, Wu T, et al. A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma. Clin Cancer Res. 2024;30:4593–4600.

Google Scholar 

Zhou H, Jiang Y, Huang Y, Zhong M, Qin D, Xie C, et al. Therapeutic inhibition of PPARα-HIF1α-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia. Cancer Lett. 2023;554:215997.

Google Scholar 

Deeks ED. Chiglitazar: first approval. Drugs. 2022;82:87–92.

Google Scholar 

He BK, Ning ZQ, Li ZB, Shan S, Pan DS, Ko BCB, et al. In vitro and in vivo characterizations of chiglitazar, a newly identified PPAR pan-agonist. PPAR Res. 2012;2012:546548.

Google Scholar 

Yu L, Lu M, Jia D, Ma J, Ben-Jacob E, Levine H, et al. Modeling the genetic regulation of cancer metabolism: interplay between glycolysis and oxidative phosphorylation. Cancer Res. 2017;77:1564–74.

Google Scholar 

So H, Lee H, Hyun SH, Cho YS, Moon SH, Choi JY, et al. Metabolic bulk volume from FDG PET as an independent predictor of progression-free survival in follicular lymphoma. Front Oncol. 2023;13:1283582.

Google Scholar 

Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4–22.

Google Scholar 

Amin R, Braza MS. The follicular lymphoma epigenome regulates its microenvironment. J Exp Clin Cancer Res. 2022;41:21.

Google Scholar 

Xie C, Zhou H, Qin D, Zheng H, Tang Y, Li W, et al. Bcl-2 inhibition combined with PPARα activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia. Cell Death Dis. 2023;14:573.

Google Scholar 

Shi Y-F, Liu L, He L-L, Ye J, Lin Z-J, Yuan D-L, et al. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway. Cell Death Dis. 2020;11:555.

Google Scholar 

Yang Q, Chen K, Zhang L, Feng L, Fu G, Jiang S, et al. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway. Cancer Lett. 2019;461:31–43.

Google Scholar 

Lees J, Hay J, Moles MW, Michie AM. The discrete roles of individual FOXO transcription factor family members in B-cell malignancies. Front Immunol. 2023;14:1179101.

Google Scholar 

Jang J-Y, Hwang I, Pan H, Yao J, Alinari L, Imada E, et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J Clin Investig. 2022;132. https://doi.org/10.1172/JCI160767.

Sun P, Cen H, Yang H, Huang R, Cai Z, Gu X, et al. PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial. Cancer Cell Int. 2025;25:39.

Google Scholar 

Jiang B, Qi J, Song Y, Li Z, Tu M, Ping L, et al. Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies. J Hematol Oncol. 2021;14:130.

Google Scholar 

Liu W, Huang Y, Yang H, Li Z, Cai Z, Wang Z, et al. A phase Ib study of linperlisib monotherapy in patients with relapsed or refractory B-cell malignancies. Blood. 2023;142:1722.

Google Scholar 

Qiu L, Jin J, Cen H, Zhou K, Xu X, Li F, et al. A study of linperlisib in the treatment of patients with relapsed and/or refractory peripheral T-cell lymphoma. Blood. 2022;140:9395–6.

Google Scholar 

Bougarne N, Weyers B, Desmet SJ, Deckers J, Ray DW, Staels B, et al. Molecular actions of PPARα in lipid metabolism and inflammation. Endocr Rev. 2018;39:760–802.

Google Scholar 

Zhou H, Qin D, Xie C, Zhou J, Jia S, Zhou Z, et al. Combinations of HDAC inhibitor and PPAR Agonist induce ferroptosis of leukemic stem cell–like cells in acute myeloid leukemia. Clin Cancer Res. 2024;30:5430–44.

Google Scholar 

Pan D-S, Wang W, Liu N-S, Yang Q-J, Zhang K, Zhu J-Z, et al. Chiglitazar preferentially regulates gene expression via configuration-restricted binding and phosphorylation inhibition of PPARγ. https://doi.org/10.1155/2017/4313561.

Eldor R, DeFronzo RA, Abdul-Ghani M. In vivo actions of peroxisome proliferator–activated receptors. Diabetes Care. 2013;36:S162–74.

Google Scholar 

Li P-P, Shan S, Chen Y-T, Ning Z-Q, Sun S-J, Liu Q, et al. The PPARα/γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Br J Pharmacol. 2006;148:610–8.

Google Scholar 

Yahiaoui OI, Nunès JA, Castanier C, Devillier R, Broussais F, Fabre AJ, et al. Constitutive AKT activation in follicular lymphoma. BMC Cancer. 2014;14:565.

Google Scholar 

Farhan M, Silva M, Xingan X, Huang Y, Zheng W, Farhan M, et al. Role of FOXO transcription factors in cancer metabolism and angiogenesis. Cells. 2020;9. https://doi.org/10.3390/cells9071586.

Ushmorov A, Wirth T. FOXO in B-cell lymphopoiesis and B cell neoplasia. Semin Cancer Biol. 2018;50:132–41.

Google Scholar 

Yadav RK, Chauhan AS, Zhuang L, Gan B. FoxO transcription factors in cancer metabolism. Semin Cancer Biol. 2018;50:65–76.

Google Scholar 

Rani M, Kumari R, Singh SP, Devi A, Bansal P, Siddiqi A, et al. MicroRNAs as master regulators of FOXO transcription factors in cancer management. Life Sci. 2023;321:121535.

Google Scholar 

Calissi G, Lam EW-F, Link W. Therapeutic strategies targeting FOXO transcription factors. Nat Rev Drug Discov. 2021;20:21–38.

Google Scholar 

Hlavac K, Pavelkova P, Ondrisova L, Mraz M. FoxO1 signaling in B cell malignancies and its therapeutic targeting. FEBS Lett. 2025;599:2911–31.

Google Scholar 

Song Y, Li Z, Wu H, Jin J, Zhou H, Zhou K, et al. A multicenter phase 2 trial of linperlisib in relapsed or refractory peripheral T/NK cell lymphomas. Blood. 2023;142:306.

Google Scholar 

Qin D, Zhou H, Zhou J, Xie C, Jia S, Yu X, et al. Therapeutic activation of PPARα inhibits transformed follicular lymphoma tumorigenesis via the FOXM1 signaling pathway. Int J Biol Sci. 2025;21:5411–27.

Google Scholar 

Farhan M, Wang H, Gaur U, Little PJ, Xu J, Zheng W. FOXO signaling pathways as therapeutic targets in cancer. Int J Biol Sci. 2017;13:815–27.

Google Scholar